Can Twist Bioscience Drop More?
Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.59 per share a year ago.
Twist Bioscience: Headwinds Are Mounting
Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also taken much of the upside off the table. Twist's NGS business continues to be a growth driver, but much of this is already reflected in the share price.
After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Responsibility Officer & Senior VP of Corporate Affairs Emily Marine Leproust - Co-Founder, Board Chair & CEO Patrick John Finn - President & COO Conference Call Participants Chad M. Wiatrowski - TD Cowen, Research Division Luke England Sergott - Barclays Bank PLC, Research Division Madeline Kendall Mollman - Wolfe Research, LLC Matthew Richard Larew - William Blair & Company L.L.C.
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.86 per share a year ago.
TWST vs. NTRA: Which Genomics Play Is a Better Buy?
Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary biotech innovators that could experience an AI tailwind like few other industries.
Twist Bioscience: Still Not There Yet
Twist Bioscience continues to grow revenue at a healthy pace, posting 23% year-over-year sales growth and beating EPS expectations in its most recent quarter. The company holds $255 million in cash and no long-term debt. Management also just announced a spin-off that should reduce operating expenses and cash burn rate. With the stock down more than 10% since the last time Twist Bioscience was put in the spotlight in late 2024, are the shares in the 'buy zone' yet?
Twist Bioscience: Expansion Efforts Continue To Face Challenges
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will help to reduce cash burn. The transaction attributes a fairly modest valuation to the business, though. This comes after the recent struggles of the biopharma business and a royalty sale, which suggests the biopharma business hasn't created much value so far.
Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. Thank you for standing by.
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
